204 related articles for article (PubMed ID: 32598795)
41. Synthesis and antitubercular evaluation of reduced lipophilic imidazo[1,2-a]pyridine-3-carboxamide derivatives.
Wang H; Wang A; Gu J; Fu L; Lv K; Ma C; Tao Z; Wang B; Liu M; Guo H; Lu Y
Eur J Med Chem; 2019 Mar; 165():11-17. PubMed ID: 30654236
[TBL] [Abstract][Full Text] [Related]
42. The Directly Observed Therapy Short-Course (DOTS) strategy in Samara Oblast, Russian Federation.
Balabanova Y; Drobniewski F; Fedorin I; Zakharova S; Nikolayevskyy V; Atun R; Coker R
Respir Res; 2006 Mar; 7(1):44. PubMed ID: 16556324
[TBL] [Abstract][Full Text] [Related]
43. Discovery of novel reversible inhibitor of DprE1 based on benzomorpholine for the treatment of tuberculosis.
Xiang W; He H; Duan X; He Z; Xu X; Liao M; Teng F; Li X; Luo T; Zeng J; Yu L; Gao C
Microbiol Spectr; 2023 Sep; 11(5):e0472122. PubMed ID: 37698416
[TBL] [Abstract][Full Text] [Related]
44. Fluorescent Benzothiazinone Analogues Efficiently and Selectively Label Dpre1 in Mycobacteria and Actinobacteria.
Sommer R; Neres J; Piton J; Dhar N; van der Sar A; Mukherjee R; Laroche T; Dyson PJ; McKinney JD; Bitter W; Makarov V; Cole ST
ACS Chem Biol; 2018 Nov; 13(11):3184-3192. PubMed ID: 30289689
[TBL] [Abstract][Full Text] [Related]
45. [Recent progress in mycobacteriology].
Okada M; Kobayashi K
Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
[TBL] [Abstract][Full Text] [Related]
46. Translational predictions of phase 2a first-in-patient efficacy studies for antituberculosis drugs.
Ernest JP; Goh JJN; Strydom N; Wang Q; van Wijk RC; Zhang N; Deitchman A; Nuermberger E; Savic RM
Eur Respir J; 2023 Aug; 62(2):. PubMed ID: 37321622
[TBL] [Abstract][Full Text] [Related]
47. Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial.
von Groote-Bidlingmaier F; Patientia R; Sanchez E; Balanag V; Ticona E; Segura P; Cadena E; Yu C; Cirule A; Lizarbe V; Davidaviciene E; Domente L; Variava E; Caoili J; Danilovits M; Bielskiene V; Staples S; Hittel N; Petersen C; Wells C; Hafkin J; Geiter LJ; Gupta R
Lancet Respir Med; 2019 Mar; 7(3):249-259. PubMed ID: 30630778
[TBL] [Abstract][Full Text] [Related]
48. Pharmacokinetics, Safety, and Tolerability of Single Oral Doses of a Novel Oxytocin Receptor Antagonist-Cligosiban-in Development for Premature Ejaculation: Three Randomized Clinical Trials in Healthy Subjects.
Osterloh IH; Muirhead GJ; Sultana S; Whaley S; van den Berg F; Atiee G
J Sex Med; 2018 Nov; 15(11):1547-1557. PubMed ID: 30341006
[TBL] [Abstract][Full Text] [Related]
49. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
Park SK; Kim JH; Kang H; Cho JS; Smego RA
Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342
[TBL] [Abstract][Full Text] [Related]
50. Early bactericidal activity of ethambutol, pyrazinamide and the fixed combination of isoniazid, rifampicin and pyrazinamide (Rifater) in patients with pulmonary tuberculosis.
Botha FJ; Sirgel FA; Parkin DP; van de Wal BW; Donald PR; Mitchison DA
S Afr Med J; 1996 Feb; 86(2):155-8. PubMed ID: 8619142
[TBL] [Abstract][Full Text] [Related]
51. [New tuberculosis drugs in resistant and multiresistant tuberculosis].
Ramírez Lapausa M; Pascual Pareja JF; Noguerado Asensio A
Med Clin (Barc); 2013 Oct; 141(7):306-13. PubMed ID: 23540388
[TBL] [Abstract][Full Text] [Related]
52. SILA-421 activity in vitro against rifampicin-susceptible and rifampicin-resistant Mycobacterium tuberculosis, and in vivo in a murine tuberculosis model.
de Knegt GJ; Bakker-Woudenberg IA; van Soolingen D; Aarnoutse R; Boeree MJ; de Steenwinkel JE
Int J Antimicrob Agents; 2015 Jul; 46(1):66-72. PubMed ID: 25951996
[TBL] [Abstract][Full Text] [Related]
53. Effect of food on the pharmacokinetics of oxycodone and naltrexone from ALO-02, an extended release formulation of oxycodone with sequestered naltrexone.
Gandelman K; Lamson M; Salageanu J; Bramson C; Matschke K; Malhotra B
Clin Pharmacol Drug Dev; 2015 Sep; 4(5):370-6. PubMed ID: 27137146
[TBL] [Abstract][Full Text] [Related]
54. Early Bactericidal Activity of AZD5847 in Patients with Pulmonary Tuberculosis.
Furin JJ; Du Bois J; van Brakel E; Chheng P; Venter A; Peloquin CA; Alsultan A; Thiel BA; Debanne SM; Boom WH; Diacon AH; Johnson JL
Antimicrob Agents Chemother; 2016 Nov; 60(11):6591-6599. PubMed ID: 27550361
[TBL] [Abstract][Full Text] [Related]
55. Model-based analysis of bactericidal activity and a new dosing strategy for optimised-dose rifampicin.
Susanto BO; Svensson EM; Te Brake L; Aarnoutse RE; Boeree MJ; Simonsson USH;
Int J Antimicrob Agents; 2023 Jun; 61(6):106813. PubMed ID: 37037318
[TBL] [Abstract][Full Text] [Related]
56. Trends in discovery of new drugs for tuberculosis therapy.
Riccardi G; Pasca MR
J Antibiot (Tokyo); 2014 Sep; 67(9):655-9. PubMed ID: 25095807
[TBL] [Abstract][Full Text] [Related]
57. [Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients].
Wada M
Kekkaku; 2001 Jan; 76(1):33-43. PubMed ID: 11211781
[TBL] [Abstract][Full Text] [Related]
58. First-Time-in-Human Study and Prediction of Early Bactericidal Activity for GSK3036656, a Potent Leucyl-tRNA Synthetase Inhibitor for Tuberculosis Treatment.
Tenero D; Derimanov G; Carlton A; Tonkyn J; Davies M; Cozens S; Gresham S; Gaudion A; Puri A; Muliaditan M; Rullas-Trincado J; Mendoza-Losana A; Skingsley A; Barros-Aguirre D
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182528
[TBL] [Abstract][Full Text] [Related]
59. Pharmacokinetics and pharmacodynamics in the development of anti-tuberculosis drugs.
Davies GR; Nuermberger EL
Tuberculosis (Edinb); 2008 Aug; 88 Suppl 1():S65-74. PubMed ID: 18762154
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
